PURPOSE: Cytomegalovirus (CMV) infection is an important complication in organ and bone marrow recipients as well as patients infected with HIV. Although screening and prophylaxis have been defined in these patients, there are few data about the frequency of CMV disease in glomerular diseases treated by immunosuppression. METHODS: We recruited 133 patients with glomerular diseases treated by immunosuppression between 2006 and 2013. Patients who had any symptoms suggestive of CMV disease were screened for viral DNA. Immunosuppressive treatments were as follows: Group 1, steroid only; Group 2, steroid with cyclophosphamide (CP); Group 3, steroid with cyclosporine A; and Group 4, steroid with mycophenolate mofetil or azathioprine. RESULTS: Patients developing CMV and non-CMV disease were compared for age, sex, renal pathology, hypertension, diabetes, baseline creatinine, and estimated glomerular filtration rate, and immunosuppressive regimen. At follow-up, 55 patients were tested for CMV disease during immunosuppressive treatment. Twenty-six patients had CMV DNA positivity of 1,112-205,500 copies/mL. Patients with CMV disease were all seen within the first 5 months of immunosuppressive treatment, and the disease was observed most commonly (14 patients, 53 %) in the first 2 months of treatment. Multiple regression analysis revealed that high baseline creatinine levels, older age, and use of steroids with CP were independent risk factors for development of CMV disease. CONCLUSIONS: CMV disease is not an uncommon complication in patients with glomerular diseases treated by immunosuppression. Further prospective studies and prophylaxis should be addressed in future studies, including particular groups of patients.
PURPOSE:Cytomegalovirus (CMV) infection is an important complication in organ and bone marrow recipients as well as patients infected with HIV. Although screening and prophylaxis have been defined in these patients, there are few data about the frequency of CMV disease in glomerular diseases treated by immunosuppression. METHODS: We recruited 133 patients with glomerular diseases treated by immunosuppression between 2006 and 2013. Patients who had any symptoms suggestive of CMV disease were screened for viral DNA. Immunosuppressive treatments were as follows: Group 1, steroid only; Group 2, steroid with cyclophosphamide (CP); Group 3, steroid with cyclosporine A; and Group 4, steroid with mycophenolate mofetil or azathioprine. RESULTS:Patients developing CMV and non-CMV disease were compared for age, sex, renal pathology, hypertension, diabetes, baseline creatinine, and estimated glomerular filtration rate, and immunosuppressive regimen. At follow-up, 55 patients were tested for CMV disease during immunosuppressive treatment. Twenty-six patients had CMV DNA positivity of 1,112-205,500 copies/mL. Patients with CMV disease were all seen within the first 5 months of immunosuppressive treatment, and the disease was observed most commonly (14 patients, 53 %) in the first 2 months of treatment. Multiple regression analysis revealed that high baseline creatinine levels, older age, and use of steroids with CP were independent risk factors for development of CMV disease. CONCLUSIONS:CMV disease is not an uncommon complication in patients with glomerular diseases treated by immunosuppression. Further prospective studies and prophylaxis should be addressed in future studies, including particular groups of patients.
Authors: A Humar; Y Lebranchu; F Vincenti; E A Blumberg; J D Punch; A P Limaye; D Abramowicz; A G Jardine; A T Voulgari; J Ives; I A Hauser; P Peeters Journal: Am J Transplant Date: 2010-03-26 Impact factor: 8.086
Authors: D Giakoustidis; A Antoniadis; I Fouzas; A Sklavos; A Giakoustidis; N Ouzounidis; D Gakis; K Koubanagiti; G Myserlis; A Tsitlakidis; I Gerogiannis; A Papagiannis; P Christoforou; T Deligiannidis; F Solonaki; G Imvrios; V Papanikolaou Journal: Transplant Proc Date: 2012-11 Impact factor: 1.066
Authors: D Lowance; H H Neumayer; C M Legendre; J P Squifflet; J Kovarik; P J Brennan; D Norman; R Mendez; M R Keating; G L Coggon; A Crisp; I C Lee Journal: N Engl J Med Date: 1999-05-13 Impact factor: 91.245
Authors: Fu L Luan; Linda J Stuckey; Jeong M Park; Daniel Kaul; Diane Cibrik; Akinlolu Ojo Journal: J Am Soc Nephrol Date: 2009-09-17 Impact factor: 10.121